Ignite Creation Date:
2025-12-24 @ 11:38 PM
Ignite Modification Date:
2025-12-25 @ 9:28 PM
Study NCT ID:
NCT03478956
Status:
TERMINATED
Last Update Posted:
2024-12-27
First Post:
2018-03-26
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A Phase I Study of Etrolizumab Followed by Open-Label Extension and Safety Monitoring in Pediatric Patients With Moderate to Severe Ulcerative Colitis or Moderate to Severe Crohn's Disease
Sponsor:
Hoffmann-La Roche
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-03-27
Start Date Type:
ACTUAL
Primary Completion Date:
2019-12-02
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-09-27
Completion Date Type:
ACTUAL
First Submit Date:
2018-03-26
First Submit QC Date:
None
Study First Post Date:
2018-03-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2020-05-19
Results First Submit QC Date:
None
Results First Post Date:
2020-08-05
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-11-11
Last Update Post Date:
2024-12-27
Last Update Post Date Type:
ACTUAL